Skip to main content
Drug Design, Development and Therapy logoLink to Drug Design, Development and Therapy
. 2022 Nov 18;16:4013–4014. doi: 10.2147/DDDT.S398020

A Novel Glycyrrhetinic Acid-Modified Oxaliplatin Liposome for Liver-Targeting and in vitro/vivo Evaluation [Retraction]

PMCID: PMC9680675  PMID: 36425307

Chen J, Jiang H, Wu Y, Li Y, Gao Y. Drug Des Devel Ther. 2015;9:2265–2275.

The Editor and Publisher of Drug Design, Development and Therapy wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figure 5 with the same images from other unrelated articles. Specifically,

The authors did not respond to our queries and no explanation for the alleged image duplication was provided. The Editor requested to retract the article and the authors were notified of this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


Articles from Drug Design, Development and Therapy are provided here courtesy of Dove Press

RESOURCES